Abstract
The impressive flow of new anti-HIV drugs--10 have been approved in the past 6 years--is giving researchers hope that they can alleviate some of the problems with current therapies (see main text). But the array of choices can be bewildering for physicians. And it is only going to get more complicated.

This publication has 0 references indexed in Scilit: